sodium stearyl sulphate | 65151-89-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: sodium stearyl sulphate
• 英文别名: sodium octadecyl sulfate；octadecyl sulfate sodium salt；Sodium stearyl sulfate；sodium;octadecyl sulfate
• CAS: 65151-89-5
• 化学式: C₁₈H₃₇O₄S*Na
• 分子量: 372.545
• InChiKey: NWZBFJYXRGSRGD-UHFFFAOYSA-M

物化性质

• 熔点：
  212.0 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.73
• 重原子数：
  24
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  sodium stearyl sulphate 以 1,4-二氧六环 、 吡啶 为溶剂， 反应 3.0h， 以1 mg的产率得到硬脂醇
  参考文献：
  名称：

  New Bioactive Sulfated Metabolites from the Mediterranean Tunicate Sidnyum turbinatum

  摘要：

  In addition to the known sodium 3,7,11,15-tetramethylhexadeca-1,19-diyl sulfate (4), the BuOH extract of the Mediterranean tunicate Sidnyum turbinatum was shown to contain four new metabolites: 1-heptadecanyl sulfate (1), 1-octadecanyl sulfate (2), sodium (2S)-2,6,10,14-tetramethylpentadeca-1,18- diyl sulfate (3), and 1-hexyl sulfate (5). Their structures were determined by spectroscopic and chemical methods. Compounds 1-5 exhibited in vitro antiproliferative activity estimated on the WEHI 164 cell line.

  DOI：

  10.1021/np000438c
• 作为产物：
  描述：

  硬脂醇 在 氯磺酸 、 sodium hydroxide 作用下， 以 氯仿 、 乙醇 为溶剂， 以65%的产率得到sodium stearyl sulphate
  参考文献：
  名称：

  Switchable viscosity triggered by CO2 using smart worm-like micelles

  摘要：

  我们报告了两种具有可切换粘度的二氧化碳响应水溶液。十八烷基硫酸钠和 2-（二甲基氨基）乙醇的溶液在有二氧化碳存在时形成粘弹性蠕虫状胶束，而在 60 °C 无二氧化碳存在时则不形成粘弹性蠕虫状胶束。硬脂酸钠和硝酸钠的另一种溶液只有在没有二氧化碳的情况下才具有高粘度。

  DOI：

  10.1039/c3cc37816k
• 作为试剂：
  描述：

  聚合甲醛 、 N-allyl-N-(3-phenyl-2-propynyl)-4-tolylsulfonamide 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer trisodium tris(3-sulfophenyl)phosphine 、 sodium stearyl sulphate 、 (±)-2,2 '-二(二-对甲苯基膦)-1,1 '-联萘 作用下， 以 水 为溶剂， 反应 1.0h， 生成 (S)-6-phenyl-2-(4-toluenesulfonyl)-2,3,3a,4-tetrahydro-1H-cyclopenta[c]pyrrol-5-one 、 6-phenyl-2-(toluene-4-sulfonyl)-2,3,3a,4-tetrahydro-1H-cyclopenta[c]pyrrol-5-one
  参考文献：
  名称：

  水性介质中烯类与甲醛的催化不对称Pauson–Khand型反应

  摘要：

  描述了水性，不对称和无CO气体的Pauson-Khand型反应的第一个例子。使用甲醛作为一氧化碳的市售替代品，亲水性膦（TPPTS）和疏水性手性膦（tolBINAP）的组合使用可使反应在水性介质中顺利进行，即使在没有一氧化碳的情况下，也可以立体选择性地进行。

  DOI：

  10.1016/j.tetlet.2004.10.100

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• [EN] 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA<br/>[FR] 5-ALKYLTHIO-7-[(4-ARYLBENZYL) AMINO] -1 (2) H-PYRAZOLO [4,3-D] PYRIMIDINES POUR LE TRAITEMENT DU LYMPHOME
  申请人：UNIV PALACKEHO

  公开号：WO2019149295A1

  公开（公告）日：2019-08-08

  The present invention relates to 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I which are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. This invention further relates to use of said derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas.

  本发明涉及式I的5-烷基硫基-7-[(4-芳基苄基)氨基]-1(2)H-吡唑并[4,3-d]嘧啶衍生物，它们是激酶的有效抑制剂，并在淋巴瘤细胞上表现出强烈的抗增殖和促凋亡特性。本发明还涉及利用这些衍生物治疗血液过度增殖性疾病，如非霍奇金淋巴瘤。
• SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF
  申请人：BETTA PHARMACEUTICALS CO., LTD

  公开号：US20210340142A1

  公开（公告）日：2021-11-04

  A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.

  I的化合物的马来酸盐、甲磺酸盐、苯磺酸盐、氢氯酸盐、磷酸盐、L-酒石酸盐、L-苹果酸盐、柠檬酸盐和富马酸盐，每种盐形式的各种晶型，以及它们的制备方法和应用。
• MEDICINAL PREPARATION
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1787661A1

  公开（公告）日：2007-05-23

  A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

  一种药物制剂具有特异性识别靶位点的配体结构和具有疏水或两性亲和性基团的两性化合物。该药物制剂采用通过引入具有适当柔韧性的链状亲水基团获得的特定结构的两性化合物，因此成为适用于药物靶向的细颗粒。 预计该药物制剂将产生持久的药理效应。可以形成具有显著靶向性能的颗粒制剂。此外，根据基质形成材料的选择，可以控制药物释放性能。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。